Cancer immunotherapy, consisting of the modulation of the immunosuppressive tumor microenvironment using antibodies targeting immune checkpoints such as the programmed cell death protein 1 (PD1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) has changed the landscape of treatment strategy in diverse advanced tumors including CRC (2–5). This evidence concerns the gene PDCD1 and neoplasm.